AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2858664 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 109
Study 2858664 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 109
Study 28573820 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage
Number of subjects: 135
Study 28573820 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 135
Study 28573820 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 135
Study 27455036 — intervention group
Group type: EXPERIMENTAL
Intervention: HYPO (mild hypohydration)
Number of subjects: 25
Study 24732289 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutezolid 600 mg BID
Number of subjects: 59
Study 24732289 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutezolid 1200 mg QD
Number of subjects: 59
Study 24732289 — intervention group
Group type: COMPARATOR
Intervention: Standard 4-drug therapy
Number of subjects: 59
Study 23193905 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with propofol‐remifentanil hydrochloride (PR)
Number of subjects: 23
Study 23193905 — intervention group
Group type: COMPARATOR
Intervention: Inhalational anesthesia with sevoflurane‐remifentanil hydrochloride (SR)
Number of subjects: 23
Study 20014162 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergic Rhinitis Nose Drops (ARND)
Number of subjects: 35
Study 20014162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 18577834 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 14
Study 18577834 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 14
Study 15793649 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.2 percent glyceryl trinitrate paste, applied to the lower anal canal, three times daily for eight weeks.
Number of subjects: 27
Study 15793649 — intervention group
Group type: COMPARATOR
Intervention: Water-soluble lubricating jelly applied to the lower anal canal.
Number of subjects: 27
Study 12781350 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nonparticipant 'manic' and passive nonparticipant 'sad' roles (abnormal social behaviour)
Number of subjects: 63
Study 12781350 — intervention group
Group type: COMPARATOR
Intervention: Active participant 'warm' and passive participant 'shy' roles (normal social behaviour)
Number of subjects: 63
Study 11310906 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol EDTA
Number of subjects: 39
Study 11310906 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 39
Study 8867904 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide, 160 mg/24 h
Number of subjects: 22
Study 8867904 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in association with standard insulin treatment)
Number of subjects: 22
Study 1346491 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition plus somatostatin (group B)
Number of subjects: 40
Study 1346491 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition alone (group A)
Number of subjects: 40
Study 6378491 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide (40 mg for 3 days) with high salt intake (Na+ intake 270 mmol/day)
Number of subjects: 6
Study 6378491 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide (40 mg for 3 days) with low salt intake (Na+ intake 20 mmol/day)
Number of subjects: 6
Study 6378491 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide (40 mg for 3 days) with high salt intake plus captopril (25 mg/6 h)
Number of subjects: 6
Study 6378491 — intervention group
Group type: EXPERIMENTAL
Intervention: Water load during high salt intake followed by frusemide
Number of subjects: 6
Study 29985820 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored lifestyle management program (TLMP) for 12 weeks, home-based after discharge.
Number of subjects: 35
Study 29985820 — intervention group
Group type: COMPARATOR
Intervention: Regular health education during hospitalization (Control group).
Number of subjects: 35
Study 29985113 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic cigarette with nicotine-containing liquid
Number of subjects: 15
Study 29985113 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional cigarette
Number of subjects: 15
Study 29985113 — intervention group
Group type: COMPARATOR
Intervention: Nicotine-free liquid (Control)
Number of subjects: 15
Study 27078992 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Guipi Decoction (MGD)
Number of subjects: 245
Study 27078992 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 245
Study 24581773 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-spot scanning laser (Allegretto Wave Eye‐Q system)
Number of subjects: 100
Study 24581773 — intervention group
Group type: COMPARATOR
Intervention: Variable-spot scanning laser (Visx Star Customvue S4 IR system)
Number of subjects: 100
Study 21680809 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily sildenafil (50 mg)
Number of subjects: 24
Study 21680809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 17876699 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate partner violence (IPV)
Number of subjects: 797
Study 17876699 — intervention group
Group type: EXPERIMENTAL
Intervention: Receptive syringe sharing (RSS)
Number of subjects: 797
Study 17876699 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-esteem and depression as mediators
Number of subjects: 797
Study 17876699 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions focused on self-esteem and depression
Number of subjects: 797
Study 17439902 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta treatment
Number of subjects: 175
Study 17439902 — intervention group
Group type: EXPERIMENTAL
Intervention: Any relapse during treatment
Number of subjects: 175
Study 17439902 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline EDSS score
Number of subjects: 175
Study 17439902 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure of IFNbeta to completely suppress relapses
Number of subjects: 175
Study 15711996 — intervention group
Group type: EXPERIMENTAL
Intervention: six-sample algorithm (preoperative, pre-excision, 5, 10, 20 and 60 min)
Number of subjects: 102
Study 15711996 — intervention group
Group type: COMPARATOR
Intervention: two-sample algorithm (preoperatively and 10 min) with additional measurement at 20 min if needed
Number of subjects: 102
Study 12468916 — intervention group
Group type: EXPERIMENTAL
Intervention: Mega-dose methylprednisolone therapy
Number of subjects: 48
Study 12468916 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 48
Study 10424370 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. taprostene
Number of subjects: 366
Study 10424370 — intervention group
Group type: COMPARATOR
Intervention: i.v. placebo
Number of subjects: 366
Study 8887169 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-2
Number of subjects: 0
Study 8887169 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH
Number of subjects: 0
Study 8887169 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-2 + GHRH
Number of subjects: 0
Study 1997878 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet CR (controlled release carbidopa/levodopa)
Number of subjects: 0
Study 1997878 — intervention group
Group type: COMPARATOR
Intervention: Conventional carbidopa/levodopa
Number of subjects: 0
Study 1997878 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet CR
Number of subjects: 0
Study 6394243 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene
Number of subjects: 40
Study 6394243 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 40
Study 6394243 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 40
Study 31365800 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of 30 ml per kilogram
Number of subjects: 3196
Study 31365800 — intervention group
Group type: COMPARATOR
Intervention: Transfusion of 20 ml per kilogram
Number of subjects: 3196
Study 29764447 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular hypertonic dextrose prolotherapy (DPT)
Number of subjects: 76
Study 29764447 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 76
Study 26758026 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Imagery (MI) training focused on the forward modeling of purposive actions, delivered through instruction videos, 9 sessions of 45 min each over 9 weeks.
Number of subjects: 2
Study 26758026 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Orientation to daily Occupational Performance (CO-OP) training focused on identifying effective cognitive strategies to increase motor competence, 9 sessions of 45 min each over 9 weeks.
Number of subjects: 2
Study 26049830 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic group (Y‐60H 3‐piece hydrophobic IOL)
Number of subjects: 60
Study 26049830 — intervention group
Group type: COMPARATOR
Intervention: Hydrophilic group (MI60 1‐piece hydrophilic IOL)
Number of subjects: 60
Study 23966446 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% heart rate reserve
Number of subjects: 80
Study 23966446 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% heart rate reserve
Number of subjects: 80
Study 23966446 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% heart rate reserve
Number of subjects: 80
Study 23966446 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 19965584 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.7 g DHA plus 0.6 g EPA
Number of subjects: 174
Study 19965584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 18182992 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose ghrelin (2 microg kg(‐1))
Number of subjects: 21
Study 18182992 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-dose ghrelin (8 microg kg(‐1))
Number of subjects: 21
Study 18182992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 17259127 — intervention group
Group type: EXPERIMENTAL
Intervention: Epi-CH (activated charcoal-epirubicin suspension)
Number of subjects: 60
Study 17259127 — intervention group
Group type: COMPARATOR
Intervention: Control (aqueous epirubicin injection)
Number of subjects: 60
Study 14652097 — intervention group
Group type: EXPERIMENTAL
Intervention: Single TMS during facilitation (controlateral hand grip and elbow flexion)
Number of subjects: 56
Study 14652097 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired TMS at rest
Number of subjects: 56
Study 14652097 — intervention group
Group type: COMPARATOR
Intervention: Single TMS during facilitation
Number of subjects: 56
Study 16948204 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive positive pressure ventilation (NPPV)
Number of subjects: 0
Study 16948204 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV
Number of subjects: 0
Study 9172969 — intervention group
Group type: EXPERIMENTAL
Intervention: tianeptine 37.5 mg/day
Number of subjects: 286
Study 9172969 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 286
Study 9172969 — intervention group
Group type: EXPERIMENTAL
Intervention: tianeptine
Number of subjects: 286
Study 8258031 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc acetate supplementation (600 mg/day) in addition to standard therapy
Number of subjects: 90
Study 8258031 — intervention group
Group type: COMPARATOR
Intervention: Only standard therapy (a diet containing 0.8 g/kg/day of protein and 90 g/day of lactulose)
Number of subjects: 90
Study 3899084 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain DTP vaccine
Number of subjects: 1075
Study 3899084 — intervention group
Group type: COMPARATOR
Intervention: Adsorbed DTP vaccine
Number of subjects: 1075
Study 30218818 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Centered Kidney Transition Care (multi-component health system intervention)
Number of subjects: 8
Study 30218818 — intervention group
Group type: COMPARATOR
Intervention: Usual nephrology care
Number of subjects: 8
Study 27455166 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics for a minimum of 5 days, stopped if body temperature was 37.8°C or less for 48 hours and no more than 1 CAP-associated sign of clinical instability.
Number of subjects: 312
Study 27455166 — intervention group
Group type: COMPARATOR
Intervention: Control group treatment duration determined by physicians.
Number of subjects: 312
Study 24981366 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate cord clamping (within 20 seconds)
Number of subjects: 100
Study 24981366 — intervention group
Group type: COMPARATOR
Intervention: Deferred cord clamping (after at least two minutes)
Number of subjects: 100
Study 22079732 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (50 mg on alternate days)
Number of subjects: 383
Study 22079732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383
Study 20542799 — intervention group
Group type: EXPERIMENTAL
Intervention: TiNOX coated stents
Number of subjects: 92
Study 18417275 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix 5mg/week for 4 weeks
Number of subjects: 140
Study 18417275 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix 10mg every 2 weeks for 2 doses
Number of subjects: 140
Study 18417275 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix 10mg/week for 4 weeks
Number of subjects: 140
Study 18417275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 15973822 — intervention group
Group type: EXPERIMENTAL
Intervention: Ariston pHc (n=50, without enamel etching and rubber dam)
Number of subjects: 31
Study 15973822 — intervention group
Group type: EXPERIMENTAL
Intervention: Solitaire I (n=49, with total etching and rubber dam)
Number of subjects: 31
Study 15973822 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of both materials
Number of subjects: 31
Study 15973822 — intervention group
Group type: COMPARATOR
Intervention: Marginal analysis for both materials
Number of subjects: 31
Study 12829912 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 119
Study 12829912 — intervention group
Group type: COMPARATOR
Intervention: CsA-ME
Number of subjects: 119
Study 11003411 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced FLASH images
Number of subjects: 36
Study 11003411 — intervention group
Group type: COMPARATOR
Intervention: Precontrast spin-echo (SE) and FLASH images
Number of subjects: 36
Study 9162304 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber, high-vegetable and -fruit dietary pattern (20% of total energy intake, 18 g/1000 kcal, 5-8 servings daily)
Number of subjects: 2079
Study 9162304 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard dietary pattern)
Number of subjects: 2079
Study 8185335 — intervention group
Group type: EXPERIMENTAL
Intervention: HCFU (long-term administration after radical treatment)
Number of subjects: 0
Study 8185335 — intervention group
Group type: COMPARATOR
Intervention: Control group (radical treatment only)
Number of subjects: 0
Study 3241278 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study 3241278 — intervention group
Group type: COMPARATOR
Intervention: Sodium restriction
Number of subjects: 0
Study 3241278 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (diuretic)
Number of subjects: 0
Study 3241278 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (ACE inhibitor)
Number of subjects: 0
Study 3241278 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nifedipine and enalapril
Number of subjects: 0
Study 3241278 — intervention group
Group type: COMPARATOR
Intervention: Combination of nifedipine with sodium restriction or hydrochlorothiazide
Number of subjects: 0
Study 31780129 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall physical activity
Number of subjects: 91905
Study 31780129 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary, moderate intensity activity, sleep duration
Number of subjects: 91905
Study 29404979 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation (HFX) of 72.0 Gy in 60 fractions given twice daily
Number of subjects: 694
Study 29404979 — intervention group
Group type: COMPARATOR
Intervention: Standard radiation of 60.0 Gy in 30 fractions given once daily
Number of subjects: 694
Study 29404979 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation (HFX)
Number of subjects: 694
Study 29404979 — intervention group
Group type: COMPARATOR
Intervention: Standard radiation
Number of subjects: 694
Study 28802594 — intervention group
Group type: EXPERIMENTAL
Intervention: 15mg ketorolac
Number of subjects: 50
Study 28802594 — intervention group
Group type: COMPARATOR
Intervention: 30mg ketorolac
Number of subjects: 50
Study 27089126 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural history data from the FAM study
Number of subjects: 226
Study 24749259 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 0
Study 24749259 — intervention group
Group type: COMPARATOR
Intervention: Trimeperidine
Number of subjects: 0
Study 21087332 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI plus generalized CFAE ablation
Number of subjects: 80
Study 21087332 — intervention group
Group type: COMPARATOR
Intervention: PVI plus selective CFAE ablation targeting only CEA regions
Number of subjects: 80
Study 19751084 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy with hypnosis plus education
Number of subjects: 124
Study 19751084 — intervention group
Group type: COMPARATOR
Intervention: Education-only control condition
Number of subjects: 124
Study 17273833 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 0.5% (15 mg)
Number of subjects: 88
Study 17273833 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric prilocaine 2% (60 mg)
Number of subjects: 88
Study 14745746 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (anastrozole, tamoxifen alone or combined)
Number of subjects: 129
Study 14745746 — intervention group
Group type: COMPARATOR
Intervention: Control group (women without breast cancer)
Number of subjects: 129
Study 11501357 — intervention group
Group type: EXPERIMENTAL
Intervention: SIS application around the gastrojejunostomy
Number of subjects: 14
Study 11501357 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SIS application)
Number of subjects: 14
Study 11501357 — intervention group
Group type: EXPERIMENTAL
Intervention: SIS application
Number of subjects: 14
Study 11501357 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14
Study 9632872 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum at 14 mmHg
Number of subjects: 52
Study 9632872 — intervention group
Group type: COMPARATOR
Intervention: Pneumoperitoneum at 10 mmHg
Number of subjects: 52
Study 9632872 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonhepatobiliary laparoscopic procedures at 14 mmHg
Number of subjects: 52
Study 8554360 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised amiloride
Number of subjects: 27
Study 8554360 — intervention group
Group type: COMPARATOR
Intervention: Control (standard inpatient treatment)
Number of subjects: 27
Study 2528578 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (7.5 mg twice daily)
Number of subjects: 23
Study 2528578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 329522 — intervention group
Group type: EXPERIMENTAL
Intervention: Sisomicin administered twice daily
Number of subjects: 100
Study 329522 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin administered three times daily
Number of subjects: 100
Study 31705465 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-family agenda setting checklist
Number of subjects: 8
Study 31705465 — intervention group
Group type: EXPERIMENTAL
Intervention: Various approaches to foster shared decision-making
Number of subjects: 8
Study 31705465 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenges in communication
Number of subjects: 8
Study 31132222 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (LCZ696) eligibility based on EMA/FDA label
Number of subjects: 5443
Study 31132222 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (LCZ696) eligibility based on PARADIGM‐HF trial
Number of subjects: 5443
Study 31132222 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (LCZ696) eligibility based on ESC guidelines
Number of subjects: 5443
Study 31132222 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry eligible patients
Number of subjects: 5443
Study 31132222 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (control group from PARADIGM‐HF)
Number of subjects: 5443
Study 28618286 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia severity
Number of subjects: 622
Study 28618286 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of depression
Number of subjects: 622
Study 28618286 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of PTSD
Number of subjects: 622
Study 28618286 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of depression and PTSD
Number of subjects: 622
Study 26081053 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon nanoparticles injected into thyroid gland (trial group)
Number of subjects: 86
Study 26081053 — intervention group
Group type: COMPARATOR
Intervention: Control group (no carbon nanoparticles)
Number of subjects: 86
Study 23904282 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin administration
Number of subjects: 11
Study 23904282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 23904282 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin administration
Number of subjects: 11
Study 20215668 — intervention group
Group type: EXPERIMENTAL
Intervention: ENDOFLAS (Zinc Oxide Eugenol and Calcium hydroxide with Iodoform)
Number of subjects: 0
Study 20215668 — intervention group
Group type: EXPERIMENTAL
Intervention: METAPEX (Calcium hydroxide with Iodoform)
Number of subjects: 0
Study 20215668 — intervention group
Group type: EXPERIMENTAL
Intervention: RC FILL (Zinc Oxide Eugenol with Iodoform)
Number of subjects: 0
Study 18819901 — intervention group
Group type: EXPERIMENTAL
Intervention: Local mild hypothermia therapy (LMH group)
Number of subjects: 52
Study 18819901 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (RT group)
Number of subjects: 52